Piper Sandler Starts Veracyte, Inc (VCYT) at Overweight

Piper Sandler analyst David Westenberg initiates coverage on Veracyte, Inc (NASDAQ: VCYT) with a Overweight rating and a price target of $66.00.

The analyst comments: “We initiate on VCYT with an OW rating and a PT of $66. The company is a rare cashgenerative dx lab anchored by two dominant genomic classifiers that resolve clinical ambiguity and guide treatment. Afirma risk-stratifies indeterminate thyroid nodules to spare patients unnecessary surgery, and we see it as the top product in the category. Decipher Prostate is the only Simon Level 1B evidence test that quantifies metastatic risk to guide treatment intensity in prostate. The product was included in 2026 NCCN Guidelines. We see these products driving teens growth for a number of years. Separately, we believe the pipeline including Prosigna, TrueMRD, and Decipher Bladder is underappreciated and represents a free call option for accelerating growth.”

For an analyst ratings summary and ratings history on Veracyte, Inc click here. For more ratings news on Veracyte, Inc click here.

Shares of Veracyte, Inc closed at $56.62 yesterday.

You May Also Be Interested In

• Citizens Assumes FTAI Infrastructure (FIP) at Market Outperform
• Citizens Starts J.B. Hunt Transport Services (JBHT) at Market Perform
• Citizens Starts Covenant Logistics Group Inc. (CVLG) at Market Outperform